A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Bookmark
Investigational drug late phase More information Active drug More information Moderate burden on patient More information

Trial Details

Sponsor: Processa Pharmaceuticals (industry)

Phase: 2

Start date: Oct. 2, 2024

Planned enrollment: 90

Trial ID: NCT06568692
Copy trial ID
More trial details at ClinicalTrials.gov More info

chevron Show Summary from Sponsor

Investigational Drug AI Analysis

chevron Show for: PCS6422 (Eniluracil)

HealthScout AI Analysis

Goal: Assess whether adding the DPD inhibitor PCS6422 to capecitabine improves antitumor activity and maintains acceptable safety compared with standard capecitabine alone in patients with advanced or metastatic breast cancer who are not candidates for anthracycline-, taxane-, PD-1–, or PARP inhibitor–based therapies.

Patients: Adults ≥18 years with histologically confirmed unresectable, advanced or metastatic breast cancer, including triple-negative or HR-positive/HER2-negative disease, measurable by RECIST 1.1, ECOG 0–1, adequate organ function, and a life expectancy ≥24 weeks. Patients must have received chemotherapy in the metastatic setting and be resistant or intolerant to taxanes and/or anthracyclines or otherwise not indicated for available therapies. Key exclusions include recent systemic therapy within 21 days or 5 half-lives, recent fluoropyrimidines or DPD inhibitors, known complete/near-complete DPD deficiency (homozygous or compound heterozygous DPYD variants), significant cardiac disease or QTc >480 ms, and pregnancy or breastfeeding.

Design: Adaptive, randomized, open-label, multi-center Phase 2 trial evaluating up to two PCS6422+capecitabine regimens versus standard-dose capecitabine monotherapy. Planned enrollment approximately 90 patients. Allocation is randomized with efficacy and safety comparisons across arms.

Treatments: Experimental arms: Single fixed dose PCS6422 40 mg combined with low-dose capecitabine administered twice daily for 7 days per cycle. Two regimens are explored: capecitabine 150 mg BID (total 300 mg/day) or 225 mg BID (450 mg/day), with protocol text also allowing 75 mg BID (150 mg/day) depending on regimen. Comparator arm: standard capecitabine 1000 mg/m2 BID (2000 mg/m2/day). PCS6422 is an irreversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the primary enzyme that catabolizes 5-FU; by inhibiting DPD, it increases exposure to active 5-FU from capecitabine while potentially reducing toxic catabolites. Early Phase 1b data in gastrointestinal cancers using this Next Generation Capecitabine approach showed disease control in a majority of evaluable patients with predominantly low-grade toxicities and no hand-foot syndrome signals in initial cohorts, supporting further evaluation in breast cancer.

Outcomes: Primary outcomes: objective response rate per RECIST 1.1 and incidence, frequency, duration, and severity of adverse events. Secondary outcomes: disease control rate, duration of response, time to response, and progression-free survival, with follow-up up to 24 weeks post end of treatment and on-treatment tumor assessments approximately every 12 weeks.

Burden on patient: Moderate. The trial uses oral therapy with tumor imaging approximately every 12 weeks, similar to standard of care. Being Phase 2 and open-label, monitoring for safety is expected to include regular clinic visits and labs to assess hematologic, hepatic, and renal function, as well as cardiac eligibility screening, but no protocol-mandated biopsies or intensive pharmacokinetic sampling are described. The addition of PCS6422 does not inherently increase visit frequency beyond routine safety assessments; however, early-cycle safety checks may be more frequent given DPD inhibition and fluoropyrimidine-related risk, contributing to a moderate overall burden.

Last updated: Oct 2025

Eligibility More information

chevron Show Criteria

Sites (13)

Sort by distance to:
Clear

Arizona Oncology Associates

Tucson, Arizona, 85711, United States

[email protected] / 520-866-0206

Status: Recruiting

FOMAT Medical Research

Oxnard, California, 93030, United States

[email protected] / 805-483-1185

Status: Recruiting

Valkyrie Clinical Trials

Los Angeles, California, 90067, United States

[email protected] / 424-535-1874

Status: Recruiting

AP Medical Research

Miami, Florida, 33165, United States

[email protected] / 305-400-8899

Status: Recruiting

Moffitt Cancer Center

Tampa, Florida, 33612, United States

[email protected] / 813-745-4933

Status: Recruiting

Northwest Cancer Center

Dyer, Indiana, 46311, United States

[email protected] / 219-924-8178

Status: Recruiting

University of Maryland Medical Center (UMMC)

Baltimore, Maryland, 21201, United States

[email protected] / 410-328-3546

Status: Recruiting

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08901, United States

[email protected] / 732-754-7788

Status: Recruiting

Clinical Research Alliance

Westbury, New York, 11590, United States

[email protected] / No phone

Status: Recruiting

Gabrail Cancer Center Research

Canton, Ohio, 44718, United States

[email protected] / 330-417-8231

Status: Recruiting

SCRI Oncology Partners

Nashville, Tennessee, 37203, United States

[email protected] / 615-712-3268

Status: Recruiting

Texas Oncology PA (Austin)

Austin, Texas, 78731, United States

[email protected] / 512-427-9400

Status: Recruiting

Texas Oncology PA (San Antonio)

San Antonio, Texas, 78240, United States

[email protected] / 210-595-5300

Status: Recruiting

Back to trials list